Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Treasury Shares: 2020-2024

Historic Treasury Shares for Aclaris Therapeutics (ACRS) over the last 5 years, with Dec 2024 value amounting to $2.1 million.

  • Aclaris Therapeutics' Treasury Shares rose 0.87% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 0.87%. This contributed to the annual value of $2.1 million for FY2024, which is 37.73% up from last year.
  • According to the latest figures from FY2024, Aclaris Therapeutics' Treasury Shares is $2.1 million, which was up 37.73% from $1.5 million recorded in FY2023.
  • Aclaris Therapeutics' Treasury Shares' 5-year high stood at $2.1 million during FY2024, with a 5-year trough of $28,895 in FY2020.
  • For the 3-year period, Aclaris Therapeutics' Treasury Shares averaged around $1.7 million, with its median value being $1.5 million (2023).
  • Data for Aclaris Therapeutics' Treasury Shares shows a peak YoY skyrocketed of 5,055.33% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Aclaris Therapeutics' Treasury Shares stood at $28,895 in 2020, then surged by 5,055.33% to $1.5 million in 2021, then climbed by 2.09% to $1.5 million in 2022, then grew by 0.08% to $1.5 million in 2023, then soared by 37.73% to $2.1 million in 2024.